Amaya Lujambio Goizueta, PhD
img_Amaya Lujambio Goizueta
ASSOCIATE PROFESSOR | Oncological Sciences
ASSOCIATE PROFESSOR | Medicine
Research Topics
Cancer, Epigenetics, Liver, Molecular Biology
Multi-Disciplinary Training Area
Cancer Biology [CAB], Immunology [IMM]
Liver Cancer Biology
Amaia Lujambio´s research group studies mechanisms of liver cancer initiation and liver cancer maintenance. In particular, we are interested in how genetic alterations in cancer cells contribute to tumorigenesis, alter treatment response, and create vulnerabilities that may be targeted therapeutically. Furthermore, we are also interested in understanding the role of cellular senescence in liver cancer initiation. Our research interests involve the establishment of in vitro and in vivo systems for the study of liver cancer as well as the rational use of shRNA libraries to identify drug targets for the disease. We utilize sophisticated mouse models of cancer, RNAi technology, valuable human cancer samples, and genetic and epigenetic profiling as key tools. The ultimate goal is to improve our understanding of liver cancer biology and to identify novel strategies that can be exploited therapeutically.

Visit theLujambio Laboratory

PhD, Spanish National Cancer Center (CNIO)

Postdoc, Cold Spring Harbor Laboratory (CSHL)

Postdoc, Memorial Sloan Kettering Cancer Center

2015

AASLD Pinnacle Research Award in Liver Diseases

AASLD

2010

EMBO Long Term Fellowship

EMBO

2010

Ph.D. Thesis Award

Universidad Autónoma de Madrid

2008

EMBO Short Term Fellowship

EMBO

2007

Eduardo Gallego Award

Fundación Francisco Cobos

2006

FPU Fellowship

Spanish Goverment

Publications

Selected Publications

SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer. Sofia Lachiondo-Ortega, Claudia M. Rejano-Gordillo, Jorge Simon, Fernando Lopitz-Otsoa, Teresa C. Delgado, Krystyna Mazan-Mamczarz, Naroa Goikoetxea-Usandizaga, L. Estefanía Zapata-Pavas, Ana García-del Río, Pietro Guerra, Patricia Peña-Sanfélix, Natalia Hermán-Sánchez, Ruba Al-Abdulla, Carmen Fernandez-Rodríguez, Mikel Azkargorta, Alejandro Velázquez-Cruz, Joris Guyon, César Martín, Juan Diego Zalamea, Leire Egia-Mendikute, Arantza Sanz-Parra, Marina Serrano-Maciá, Irene González-Recio, Monika Gonzalez-Lopez, Luis Alfonso Martínez-Cruz, Patrizia Pontisso, Ana M. Aransay, Rosa Barrio, James D. Sutherland, Nicola G.A. Abrescia, Félix Elortza, Amaia Lujambio, Jesus M. Banales, Raúl M. Luque, Manuel D. Gahete, Asís Palazón, Matias A. Avila, Jose J. Jose, Supriyo De, Thomas Daubon, Antonio Díaz-Quintana, Irene Díaz-Moreno, Myriam Gorospe, Manuel S. Rodríguez, María Luz Martínez-Chantar. Cell Reports

Master Transcription Factor Reprogramming Unleashes Selective Translation Promoting Castration Resistance and Immune Evasion in Lethal Prostate Cancer. Sandra Santasusagna, Shijia Zhu, Vijayakumar Jawalagatti, Marc Carceles-Cordon, Adam Ertel, Saioa Garcia-Longarte, Won Min Song, Naoto Fujiwara, Peiyao Li, Isabel Mendizabal, Daniel P. Petrylak, William Kevin Kelly, E. Premkumar Reddy, Liguo Wang, Matthew J. Schiewer, Amaia Lujambio, Jeffrey Karnes, Karen E. Knudsen, Carlos Cordon-Cardo, Haidong Dong, Haojie Huang, Arkaitz Carracedo, Yujin Hoshida, Veronica Rodriguez-Bravo, Josep Domingo-Domenech. Cancer Discovery

Monocyte depletion enhances neutrophil influx and proneural to mesenchymal transition in glioblastoma. Zhihong Chen, Nishant Soni, Gonzalo Pinero, Bruno Giotti, Devon J. Eddins, Katherine E. Lindblad, James L. Ross, Montserrat Puigdelloses Vallcorba, Tanvi Joshi, Angelo Angione, Wes Thomason, Aislinn Keane, Nadejda M. Tsankova, David H. Gutmann, Sergio A. Lira, Amaia Lujambio, Eliver E.B. Ghosn, Alexander M. Tsankov, Dolores Hambardzumyan. Nature Communications

View All Publications

Cancer Precision Medicine Retreat -- Session 5: Amaia Lujambio

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Lujambio Goizueta during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Asian Pacific Association for the Study of the Liver
  • Fundación Ramón Areces
  • Oregon Health & Science University
  • Memorial Sloan Kettering Cancer Center
  • Society for Immunotherapy of Cancer

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.